Faraday Pharmaceuticals
Seattle
About Faraday Pharmaceuticals
Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury. It has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements developed in the lab of Dr. Mark Roth at the Fred Hutchinson Cancer Center. The company was founded in 2014 and is located in Seattle, Washington.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $140.8M
- Funding stage: Late Stage Venture
- Last round: Series C (Nov 2022)
- Website: faradaypharma.com
- Phone: 206-452-8700
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/faraday-pharmaceuticals-10868 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.